SUMMARY
Each full-strength TussiCaps™ (hydrocodone polistirex and chlorpheniramine polistirex) extended-release capsule contains hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate and chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate. Each half-strength TussiCaps™ (hydrocodone polistirex and chlorpheniramine polistirex) extended-release capsule contains hydrocodone polistirex equivalent to 5 mg of hydrocodone bitartrate and chlorpheniramine polistirex equivalent to 4 mg of chlorpheniramine maleate. TussiCaps™ extended-release capsules provide up to 12-hour relief per dose. Hydrocodone is a centrally-acting narcotic antitussive. Chlorpheniramine is an antihistamine. TussiCaps™ extended-release capsules are for oral use only.
TussiCaps™ (hydrocodone polistirex and chlorpheniramine polistirex) extended-release capsules are indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older.
|
|
NEWS HIGHLIGHTS
Clinical Trials Related to Tussicaps Extended-Release (Hydrocodone / Chlorpheniramine)
Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex� Pennkinetic� Extended Release Oral Suspension [Completed]
The objective of this open-label, randomized, two-period, crossover study was to evaluate
the oral bioavailability of the Mallinckrodt extended release test capsule formulation of
chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a
commercially available extended release oral suspension of chlorpheniramine
polistirex/hydrocodone polistirex (Tussionex® Pennkinetic® Extended Release Oral Suspension,
Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fed conditions.
Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex� Pennkinetic� Extended Release Oral Suspension [Completed]
The objective of this open-label, randomized, two-period, crossover study was to evaluate
the oral bioavailability of the Mallinckrodt extended release test capsule formulation of
chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a
commercially available extended release oral suspension of chlorpheniramine
polistirex/hydrocodone polistirex (Tussionex® Pennkinetic® Extended Release Oral Suspension,
Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fasting
conditions.
|
|
Page last updated: 2008-05-12
|